相关实验视频

Updated: Jun 6, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

有条件激活的免疫毒素具有延长的半衰期,可以增强抗瘤活性

Xi Wang¹, Yu Ding¹, Shuang Li²

¹State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Sciences, Cancer Biology Center, Frontiers Science Center for New Organic Matter, College of Life Sciences, Nankai University, Tianjin 300071, PR China.

International journal of pharmaceutics

|November 27, 2024

概括

一种新型免疫毒素,NbHSA-uPA-A1-PE24,证明了半衰期的延长和瘤的向传递. 这种工程癌症疗法显示出强大的抗瘤效果,并提高了安全性,为临床应用提供了新的策略.

科学领域:

在瘤学瘤学.
生物技术是生物技术.
药物开发药物开发

背景情况:

免疫毒素对癌症治疗有希望,但面临着短半衰期和非向毒性等挑战.
现有的免疫毒素往往缺乏特异性,导致健康组织表达抗原的副作用.

研究的目的:

设计和评估一种瘤条件免疫毒素,NbHSA-uPA-A1-PE24,具有改善的药理动力学和降低的毒性.
通过有针对性的输送和条件激活来提高基于免疫毒素的癌症治疗的疗效和安全性.

主要方法:

通过通过UPA可切割的链接器将抗HSA纳米体 (NbHSA) 与免疫毒素 (A1-PE24) 融合为免疫毒素.
在临床前癌症模型 (胰腺,胃) 中评估了免疫毒素的半衰期,瘤丰富和抗瘤活性.

主要成果:

新型免疫毒素在循环中表现出显著延长的半衰期.
在多个临床前模型中,nbHSA-uPA-A1-PE24证明了增强的瘤积累和强大的抗瘤疗效.
设计策略成功降低了对健康组织的毒性.

结论:

瘤条件免疫毒素NbHSA-uPA-A1-PE24为癌症治疗提供了一个有前途的策略,其安全性和有效性得到了提高.
这种方法为开发具有增强治疗潜力的下一代免疫毒素提供了新的范式.

关键词:

有条件的激活方式半衰期半衰期半衰期免疫毒素是一种免疫毒素.梅索他林是其中一种蛋白质.在 uPAPA 中,

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...